Marker Therapeutics, Inc.

Monthly Archives: January 2015

Positive Phase 1 Immune Responses in All Evaluable Ovarian and Breast Cancer Patients Advances Vaccine to Phase II Clinical Trials

…Analysis of Phase I Trial indicates Safety and Positive Immune Response Data in 21 of 21 Patients Administered Folate Receptor Alpha Vaccine for Breast and Ovarian Cancers

January 12, 2015, Seattle WA, TapImmune Inc. (OTCQB: TPIV) is extremely pleased to report the completion of data analysis from all 21 evaluable patients treated in a Phase I clinical trial.

Read More

TapImmune, Inc. Announces $1,464,000 Million Registered Direct Offering

…Exercise in Full of Strategically Designed Warrant Package

Would Result in $34,404,000 in Additional Funding

Seattle, January 12, 2015 — TapImmune, Inc. (the “Company”), (otcqb:TPIV), today announced that it has entered into a definitive agreement with institutional investors for a registered direct placement of 7,320,000 units at $0.20 per unit, with each “unit” consisting of one share of common stock and one of each of the following warrants:

Series A warrants to purchase up to an aggregate of 7,320,000 shares of common stock with an exercise price of $1.50 per share (such exercise price subject to full price protection for dilutive issuances) and a term of five years;

Read More